News
Neuroplast spinal cord injury study milestone
Neuroplast, a company concentrating on cell-based treatments for neurodegenerative diseases, has successfully completed patient inclusion for its phase 2 trial.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Neuroplast, a company concentrating on cell-based treatments for neurodegenerative diseases, has successfully completed patient inclusion for its phase 2 trial.